Oil prices hold sharp losses with focus on secondary India tariffs
Investing.com - Piper Sandler maintained its Overweight rating and $120.00 price target on GeneDx (NASDAQ:WGS), now valued at nearly $3 billion, following the company’s recent earnings report. According to InvestingPro data, the stock maintains a "GOOD" financial health score, with analysts’ targets ranging from $95 to $125.
The research firm raised its revenue projections for GeneDx after the company beat expectations and increased its own guidance last week. The company has demonstrated strong momentum with 48.7% revenue growth in the last twelve months.
Piper Sandler identified potential upside to average selling prices for this year, along with possible revenue and operating margin improvements in subsequent years.
The firm described GeneDx as a "compelling multi-year growth story" in its research note, highlighting the company’s strategic positioning in the genetic testing market.
Piper Sandler believes GeneDx is well-positioned to expand its services beyond geneticists to neonatal intensive care units (NICU), pediatricians, and eventually the broader newborn screening market.
In other recent news, GeneDx Holdings Corp reported impressive financial results for the second quarter of 2025. The company significantly exceeded earnings and revenue forecasts, with earnings per share reaching $0.50, far surpassing the anticipated $0.12. Revenue for the quarter was reported at $102.7 million, which is a 20.19% increase over the forecasted $85.45 million. Following these results, BTIG raised its price target for GeneDx to $125 from $100, while maintaining a Buy rating. BTIG highlighted the company’s strong performance, noting a "strong bounce-back" in Q2 that exceeded top-line expectations by more than $17 million and surpassed bottom-line forecasts by $15 million. These developments mark a significant achievement for GeneDx in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.